Eledon Pharmaceuticals 미래 성장

Future 기준 확인 0/6

Eledon Pharmaceuticals 의 수익은 연간 33% 감소할 것으로 예상되는 반면, 연간 수익은 87.2% 로 증가할 것으로 예상됩니다. 87.2% 연간. EPS는 연간 10.8% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-33.0%

수익 성장률

-10.8%

EPS 성장률

Biotechs 수익 성장	42.4%
매출 성장률	87.2%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	20 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:2TK - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	-79	-106	N/A	2
12/31/2025	N/A	-81	-84	N/A	4
12/31/2024	N/A	-20	N/A	N/A	5
9/30/2024	N/A	-25	-37	-37	N/A
6/30/2024	N/A	-89	-38	-38	N/A
3/31/2024	N/A	-129	-38	-38	N/A
12/31/2023	N/A	-117	-40	-40	N/A
9/30/2023	N/A	-145	-40	-40	N/A
6/30/2023	N/A	-145	-32	-32	N/A
3/31/2023	N/A	-89	-30	-30	N/A
12/31/2022	N/A	-88	-28	-28	N/A
9/30/2022	N/A	-38	-28	-28	N/A
6/30/2022	N/A	-38	-31	-31	N/A
3/31/2022	N/A	-36	-32	-32	N/A
12/31/2021	N/A	-35	-29	-29	N/A
9/30/2021	N/A	-32	-29	-29	N/A
6/30/2021	N/A	-28	-23	-23	N/A
3/31/2021	N/A	-23	-18	-18	N/A
12/31/2020	N/A	-23	-15	-15	N/A
9/30/2020	N/A	-21	-8	-8	N/A
6/30/2020	N/A	-18	-10	-10	N/A
3/31/2020	N/A	-19	-12	-12	N/A
12/31/2019	N/A	-16	-14	-14	N/A
9/30/2019	N/A	-16	-15	-15	N/A
6/30/2019	N/A	-17	-15	-15	N/A
3/31/2019	N/A	-16	-14	-14	N/A
12/31/2018	N/A	-14	-12	-12	N/A
9/30/2018	N/A	-12	-11	-11	N/A
6/30/2018	N/A	-11	N/A	-12	N/A
3/31/2018	N/A	-13	N/A	-16	N/A
12/31/2017	N/A	-11	N/A	-15	N/A
9/30/2017	N/A	-9	N/A	-14	N/A
6/30/2017	N/A	-6	N/A	-12	N/A
3/31/2017	N/A	-1	N/A	-5	N/A
12/31/2016	N/A	-1	N/A	-5	N/A
9/30/2016	N/A	-1	N/A	-6	N/A
12/31/2015	N/A	-1	N/A	-4	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 2TK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: 2TK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: 2TK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: 2TK 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: 2TK 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 2TK 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Eledon Pharmaceuticals 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

New major risk - Revenue and earnings growth

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought €73k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: €10.50

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

New 90-day low: €12.50

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

New 90-day high: €21.50

Novus Therapeutics, Inc. announced that it has received $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. announced that it expects to receive $108.15 million in funding from a group of investors

New 90-day high - €0.89

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

New 90-day low - €0.31

New 90-day low - €0.35

Novus Therapeutics, Inc.(NasdaqCM:NVUS) dropped from Russell Microcap Value Index

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견